Artiva Biotherapeutics (ARTV) Status update summary

Strategic Positioning and Opportunity

• Deep B-cell depletion is a leading mechanism in autoimmune disease, with high industry interest and multiple modalities in development.

• Lead indication is refractory rheumatoid arthritis (RA), representing a large commercial opportunity with significant unmet need.

• AlloNK aims to deliver CAR-T-like efficacy with improved scalability, cost, and safety for community settings.

• Recent $300 million financing extends operational runway into 2029, supporting pivotal trial completion.

Clinical Data and Efficacy

• Over 70 autoimmune and 40 cancer patients treated with AlloNK, showing consistent activity and no discontinuations due to adverse events.

• In refractory RA, 71% of patients in the Phase 2a basket trial achieved ACR50 response at six months, with durable responses and no loss of efficacy or need for high-dose steroids or new biologics.

• Durable responses observed, with no loss of response or need for new targeted therapies as of data cutoff.

• Initial data in Sjögren disease and systemic sclerosis showed substantial improvements in disease activity, function, and clinical response measures, including normalization of salivary flow and improved skin scores.

Safety and Tolerability

• AlloNK plus rituximab demonstrated a favorable safety profile compared to CAR-T and T-cell engagers, with low rates of severe infections and no cytokine release syndrome or ICANS.

• Only two hospitalizations in 55 patients within 28 days, neither related to treatment; no hospitalizations for infection in this period.

• Grade 3 or higher infection rate was 2%.

• Most common adverse events were consistent with known effects of rituximab or Cy/Flu conditioning.